|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Fecal immunochemical test accuracy in average-risk colorectal cancer screening显示文摘AIM:To assess the fecal immunochemical test(FIT)accuracy for colorectal cancer(CRC)and advanced neoplasia(AN)detection in CRC screening.METHODS:We performed a multicentric,prospective,double blind study of diagnostic tests on asymptomatic average-risk individuals submitted to screening colonoscopy.Two stool samples were collected and the fecal hemoglobin concentration was determined in the first sample(FIT1)and the highest level of both samples(FITmax)using the OC-sensor.Areas under the curve(AUC)for CRC and AN were calculated.The best FIT1and FITmax cut-off values for CRC were determined.At this threshold,number needed to scope(NNS)to detect a CRC and an AN and the cost per lesion detected were calculated.RESULTS:About 779 individuals were included.An AN was found in 97(12.5%)individuals:a CRC in 5(0.6%)and an advanced adenoma(≥10 mm,villous histology or high grade dysplasia)in 92(11.9%)subjects.For CRC diagnosis,FIT1 AUC was 0.96(95%CI:0.95-0.98)and FITmax AUC was 0.95(95%CI:0.93-0.97).For AN,FIT1 and FITmax AUC were similar(0.72,95%CI:0.66-0.78 vs 0.73,95%CI:0.68-0.79,respectively,P=0.34).Depending on the number of determinations and the positivity threshold cut-off used sensitivity for AN detection ranged between 28%and 42%and specificity between 91%and 97%.At the best cut-off point for CRC detection(115 ng/mL),the NNS to detect a CRC were 10.2 and 15.8;and the cost per CRC was 1814€and 2985€on FIT1 and FITmax strategies respectively.At this threshold the sensitivity,NNS and cost per AN detected were 30%,1.76,and 306€,in FIT1 strategy,and 36%,2.26€and 426€,in FITmax strategy,respectively.CONCLUSION:Performing two tests does not improve diagnostic accuracy,but increases cost and NNS to detect a lesion. | Vicent Hernandez Joaquin Cubiella M Carmen Gonzalez-Mao Felipe Iglesias Concepción Rivera M Begoa Iglesias Lucía Cid Ines Castro Luisa de Castro Pablo Vega Jose Antonio Hermo Ramiro Macenlle Alfonso Martínez-Turnes David Martínez-Ares Pamela Estevez Estela Cid M Carmen Vidal Angeles López-Martínez Elisabeth Hijona Marta Herreros-Villanueva Luis Bujanda Jose Ignacio Rodriguez-Prada the COLONPREV study investigators | 2014 | World Journal of Gastroenterology2014，20，4： | 4 |
| 2 | Tissue‐print and squash real‐time PCR for direct detection of ‘ C andidatus Liberibacter’ species in citrus plants and psyllid vectors显示文摘 | E. Bertolini R. T. A. Felipe A. V. Sauer S. A. Lopes A. Arilla E. Vidal F. A. A. Mour?o Filho W. M. C. Nunes J. M. Bové M. M. López M. Cambra | 2014 | Plant Pathol2014，，5： | 1 |
| 3 | Current treatment landscape for oligometastatic non-small cell lung cancer显示文摘The management of patients with advanced non-small cell lung carcinoma(NSCLC)has undergone major changes in recent years.On the one hand,improved sensitivity of diagnostic tests,both radiological and endoscopic,has altered the way patients are staged.On the other hand,the arrival of new drugs with antitumoral activity,such as targeted therapies or immunotherapy,has changed the prognosis of patients,improving disease control and prolonging survival.Finally,the development of radiotherapy and surgical and interventional radiology techniques means that radical ablative treatments can be performed on metastases in any location in the body.All of these advances have impacted the treatment of patients with advanced lung cancer,especially in a subgroup of these patients in which all of these treatment modalities converge.This poses a challenge for physicians who must decide upon the best treatment strategy for each patient,without solid evidence for one optimal mode of treatment in this patient population.The aim of this article is to review,from a practical and multidisciplinary perspective,published evidence on the management of oligometastatic NSCLC patients.We evaluate the different alternatives for radical ablative treatments,the role of primary tumor resection or radiation,the impact of systemic treatments,and the therapeutic sequence.In short,the present document aims to provide clinicians with a practical guide for the treatment of oligometastatic patients in routine clinical practice. | Javier Garde-Noguera Margarita Martín-Martín Andres Obeso Miriam López-Mata Inigo Royo Crespo Lira Pelari-Mici O Juan Vidal Xabier Mielgo-Rubio Juan Carlos Trujillo-Reyes Felipe Couñago | 2022 | World Journal of Clinical Oncology2022，13，6： | 0 |
| 4 | Dendrimer nanocarriers drug action: perspective for neuronal pharmacology显示文摘General aspects:Currently,several strategies have been used to overcome common problems found in pharmacological therapies,such as insolubility,reduced bioavailability and low specificity of drugs.One of the most promising alternatives proposed is the use of dendrimeric drug nanocarriers,polymeric chemical structures of diverse nature that contain,transport and deliver the desired drug in biological systems.One of the dendrimers that has been most successfully used is based on polyamidoamine(PAMAM).PAMAM are organized from a central molecule of ethylenediamine that gives way to expansive growing layers(generations)terminating in a surface of primary amines that are positively charged at physiological p H.This architecture determines the presence of intramolecular | Felipe Vidal Leonardo Guzman | 2015 | Neural Regeneration Research2015，10，7： | 0 |
您所在的机构暂未开通此部分的功能，请联系管理员